Home News

First half 2021 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Wed, 28/07/2021 - 00:00 0 min
Download related document
No votes yet
 
Related
ROVI reports operating revenue growth of 24% and EBITDA growth of 83%
Operating revenue increased by 24% to 270.8 million euros in the first nine months of 2019, mainly driven by the strength of the...
5 min
07/11/2019
ROVI announces the construction of a second heparin plant in Granada
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the future construction of a new manufacturing plant for the active substance...
3 min
05/09/2019
ROVI increases its operating revenue by 21% and EBITDA by 99%
Operating revenue increased by 21% to 177.5 million euros in the first half of 2019, mainly driven by the strength of the specialty...
6 min
30/07/2019